These nanoparticles can modify CAR-T cells in vivo [215], regulate CD4+ T cell function [216], inhibit the expression of tumor-associated immunosuppressive cells [217], and control the release of immunosuppressive agents like IL-2 and transforming growth factor-β (TGF-β) [218]. The gene discussed is CD4; the disease is neoplasm.